Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

Prostate cancer has long been one of Canada’s most prevalent, yet under-discussed health threats. It is the most commonly ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate ...

Residual cancer after neoadjuvant therapy predicts recurrence years later in men undergoing surgery for high-risk prostate cancer.

There will be about 299,010 new cases of prostate cancer diagnosed this year, according to the American Cancer Society.

Kevin P. Martin Jr. was shocked to learn he had stage 4 prostate cancer at 61. The endurance athlete has vowed to stay active ...

A team of University of Kentucky Markey Cancer Center researchers have found the mechanism that grants prostate cancer resistance to enzalutamide, a frequently used drug treatment.